For most investors, generating consistent income alongside capital appreciation is a common goal. For those seeking a blend ...

According to Report Ocean, the US Urinary Tract Infection (UTI) Therapeutics market is anticipated to grow at a CAGR of ~$% between 2022-2028 owing to rise in cases of UTIs, technological advancements ...

We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at ...

These four S&P 500 stocks pay 6% and higher dividends, have Buy ratings at top Wall Street firms, and are offering excellent ...

Cambridge: Atavistik Bio, a biotechnology company has announced that it has entered into a research collaboration with Pfizer ...

These five high-yield dividend stocks have the potential to deliver positive total returns and dependable passive income.

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...

The FDA had approved Tagrisso for a similar use in September. FDA Approves Pfizer’s Braftovi for First-Line Colorectal Cancer The FDA approved Pfizer’s Braftovi in combination with Erbitux ...

Gem­ma­Bio, a com­pa­ny found­ed by gene ther­a­py pi­o­neer Jim Wil­son, has raised $34 mil­lion in seed fund­ing to try and re­sus­ci­tate the floun­der­ing gene ther­a­py field.

Pfizer Inc announced that the US Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil, leucovorin, and ...

Pfizer’s Braftovi (encorafenib) regimen has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat metastatic colorectal cancer (mCRC). The drug has been authorised ...